Cachexia. Cachexia
Conditions
Interventions
Intervention 1: Megestrol acetate 160mg BD+Celecoxib 100mg BD for 2 months in intervention group. Intervention 2: Megestrol acetate 160mg BD for 2 months in control group.
Treatment - Drugs
Megestrol acetate 160mg BD+Celecoxib 100mg BD for 2 months in intervention group
Megestrol acetate 160mg BD for 2 months in control group
Sponsors
Mazandaran University of Medical Scienses
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age of more than 18 y; Confirmed diagnosis of gastroesophageal or colorectal cancer in any stage; Hope for survival of at least 4 month; More than 5% weight loss in the past 3 to 6 month or more than 5% weight loss in comparison to the weight before disease or a body weight less than 5% of ideal body weight or a BMI (Body Mass Index) of less than 20; Palliative treatments or chemotherapy is allowed Exclusion criteria: Mechanical obstruction in alimentary tract; Any treatment which induce weight gain like glucocorticoids; Diagnosis of diabetes mellitus with concomitant insulin therapy; Uncompensated cardiac failure with ejection fraction of less than 30% or with New York Heart Association function class of 3 or 4; Uncontrolled Hypertention with systolic blood pressure greater than140 mmHg or diastolic blood pressure greater than 90 mmHg; History of myocardial infarction; History of unstable angina; History of Cerebro-vascular accidents; Uncontrolled cardiac dysrhythmias; Inflammatory bowel disease; Gastrointestinal ulcers or history of GI bleedings
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: 2 month from baseline. Method of measurement: EORTC QLQ-C30 questionnare.;Weight. Timepoint: 2 month from baseline. Method of measurement: Scale with precision of 0.1 Kg. | — |
Secondary
| Measure | Time frame |
|---|---|
| Glasgow prognostic score (GPS). Timepoint: 2 month from baseline. Method of measurement: calculated based on Albumin and CRP.;IL-1. Timepoint: 2 month from baseline. Method of measurement: ELISA.;IL-6. Timepoint: 2 month from baseline. Method of measurement: ELISA.;TNF-alpha. Timepoint: 2 month from baseline. Method of measurement: ELISA.;Appetite. Timepoint: 2 month from baseline. Method of measurement: Visual analogue scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEbrahim Salehifar
Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences
Outcome results
None listed